Ramneesh Trehan, MD
Psychiatry · Malone, NYNPI 1801829270
Payments from drug & device makers
Across 16 payments — averaging $25.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$117
- Johnson & Johnson$94
- E.r. Squibb & Sons, L.L.C.$43
- Otsuka America Pharmaceutical, Inc.$38
- Daiichi Sankyo Inc.$22
- Ironshore Pharmaceuticals Inc.$21
- plus $76 from 4 others
What the payments were for
- Food & beverage$410100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 1 | $117 |
| Johnson & Johnson | 5 | $94 |
| E.r. Squibb & Sons, L.L.C. | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Lundbeck LLC | 1 | $20 |
| Braeburn Inc. | 1 | $19 |
| Indivior Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$117
How this compares
$410 in reported general payments places this provider in the 65th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 12 | $43,151 |
| VraylarCariprazine Hcl | 17 | $20,062 |
| TrintellixVortioxetine Hydrobromide | 13 | $14,115 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 216 | $13,068 |
| Prazosin Hcl | 27 | $1,285 |
| Buprenorphine Hcl | 13 | $1,024 |
| Mirtazapine | 34 | $826 |
| Gabapentin | 75 | $813 |
| Buspirone Hcl | 28 | $704 |
| Clonazepam | 86 | $638 |
| Duloxetine Hcl | 24 | $581 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 14 | $515 |
| Citalopram HbrCitalopram Hydrobromide | 37 | $461 |
| Alprazolam | 16 | $362 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 33 | $301 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Malone
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
- Inna Yuryev-GolgerBrooklyn$3M
- Subhdeep VirkBuffalo$3M
- Paul EderNew York$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.